P03.29 Characterization of treatment-induced adaptive immune responses in pancreatic ductal adenocarcinoma
Sign Up to like & getrecommendations! Published in 2020 at "Journal for ImmunoTherapy of Cancer"
DOI: 10.1136/jitc-2020-itoc7.67
Abstract: Background Pancreatic ductal adenocarcinoma (PDAC) is a highly aggressive malignancy marked by poor prognosis and profound drug resistance characterized in more than 90% of cases by KRAS mutations. To recapitulate central aspects of PDAC, we… read more here.
Keywords: pdac; none; combinatorial treatment; treatment ... See more keywords
High-throughput screen in vitro identifies dasatinib as a candidate for combinatorial treatment with HER2-targeting drugs in breast cancer
Sign Up to like & getrecommendations! Published in 2023 at "PLOS ONE"
DOI: 10.1371/journal.pone.0280507
Abstract: Human epidermal growth factor receptor 2-positive (HER2+) breast cancer is an aggressive subtype of this disease. Targeted treatment has improved outcome, but there is still a need for new therapeutic strategies as some patients respond… read more here.
Keywords: breast cancer; treatment; her2; combinatorial treatment ... See more keywords
A novel combinatorial treatment option for metastatic uveal melanoma
Sign Up to like & getrecommendations! Published in 2018 at "Oncotarget"
DOI: 10.18632/oncotarget.25445
Abstract: Uveal melanoma (UM) is the most frequent intraocular tumor in adult patients. When metastases occur, systemic therapy with alkylating agents (fotemustine or dacarbazine (DTIC)) has shown only modest efficacy. The common chemotherapeutic drug doxorubicin (DOX)… read more here.
Keywords: melanoma; novel combinatorial; uveal melanoma; creb knockdown ... See more keywords